Ninth Demures on Isomer: Kelly and DEA Authority to Temporarily Schedule Controlled Substance Isomers
Q: What do you get when
the DEA temporarily criminalizes an isomer, without making any findings about its
dangerousness or whether it is prone to abuse?
A: 70 months.
United States v. Kelly, 2017 WL
4875214 (9th Cir. Oct. 30, 2017), decision available here.
Hard fought appeal by AFPD Erica Choi, District of Nevada Office of the
Federal Public Defender.
Facts: Kelly sold an undercover officer what was reported
to be MDMA – but it was actually “ethylone.” Id. at *3. Ethylone is a “positional isomer” of “butylone.” Id. at *4.
(“An isomer is a molecule with the same
chemical formula as another molecule, but its atoms are arranged in a different
sequence. For example, butylone and ethylone share the chemical formula C12H15NO3,
but they differ in the location of a functional group.”) Id.
At the time, butylone was a “designer drug”
listed as a Schedule I controlled substance under the DEA’s temporary scheduling authority. Id. at *3. The DEA made specific
findings as to butylone (the “parent drug.”) Id. at *6. It did not
make findings as to ethylone, an isomer of butylone, and it did not mention this
isomer in the required letter to the Secretary of Health and Human Services. Id. at *3.
After Kelly was charged with possession with
intent to distribute ethylone, a Schedule I controlled substance, he moved to
dismiss. Id. at *4. The district
court denied his request for an evidentiary hearing, to present expert testimony
that an isomer does not necessary have the same effects and properties as the
substance (parent drug) itself. Id. at
*4 & n.7. The court also denied the Fed. R. Crim. P. 12(b)(3)(B)(v) motion
to dismiss. Id.
Kelly entered a conditional plea and was sentenced
to seventy months of custody. Id. at
*5.
Issue(s): “Kelly argues that the DEA did not place ethylone
into Schedule I as a matter of law because §§ 811(h) and 812(b) require that
the DEA name and make findings for each individual isomer it intends to
temporarily schedule. He contends that the DEA’s failure to do so violated the
Constitution’s non-delegation doctrine.” Id.
at *5.
Held: “Kelly’s
argument is misreading the CSA. The plain language of the statute permits the
DEA to make findings for a parent substance as a basis to temporarily schedule
that substance and its isomers. The DEA properly made findings for butylone and
provided notice covering butylone and its isomers as required in §§ 811(h) and
812(b). In following the congressional mandate, we hold the DEA did not violate
the non-delegation process.” Id.
at *6.
Of Note: This decision has no real relevance anymore to
butylone and ethylone: that drug and isomer were permanently added as permanent
Schedule I substances on March 1, 2017. See
id. at *3 & n.5. The decision’s significance is its holding that the
DEA’s findings on a parent drug for a
temporary Schedule I designation covers isomers
of that parent drug. Id. at*6.
Curiously, the DEA’s permanent scheduling process (a process
with far fewer protections, checks and balances than the temporary procedures) generally
only covers optical isomers. Id. at *4.
There is much angst over the
dangers of designer drugs in Kelly,
and touted deference to Congressional intent, but the holding itself is a
worrisome take on DEA’s power to criminalize drugs on an expedited schedule,
with comparatively little review or notice.
How to Use:
What happens
when two established policies for reading a statute or regulation come into conflict: the
rule of lenity, and Chevron
deference? The magistrate judge in Kelly
gave the nod to Chevron, holding that
the rule of lenity did not apply to an administrative regulation. Id. at *4.
Judge
Tallman avoids this knotty problem, finding the reg was plain so the rule of
lenity didn’t come into play. Id. at
*8 & n.8.
An issue that lives on to
be fought another day (not yet resolved by the Supreme Court, reports Kelly).
For Further
Reading: What could be worse than the FBI using a
snitch that was an undocumented alien, who lied about his identity?
Loaning him out to another law enforcement agency
– without telling them. See L.A.
Times article, here.
Image
of ethylone from https://www.rechemco.to/media/catalog/product/cache/16/image/650x/040ec09b1e35df139433887a97daa66f/e/t/ethylone-eu.jpg
.
Steven Kalar,
Senior Litigator N.D. Cal. Website at www.ndcalfpd.org
.
Labels: DEA, Designer Drugs, Non-delegation doctrine, Rule of Lenity, Schedule I, Tallman
0 Comments:
Post a Comment
<< Home